ScreenPoint Medical Expands Capabilities with Biomediq A/S Acquisition
Deal News | Jan 08, 2025 | PR Newswire Cision ScreenPoint Medical
ScreenPoint Medical has announced the acquisition of Biomediq A/S, a leader in quantitative imaging biomarkers. This acquisition aims to bolster ScreenPoint's capabilities in breast cancer risk assessment by integrating Biomediq’s expertise in automatic computer analysis of 2D and 3D mammograms. The partnership between these two entities is anticipated to enhance the predictive power of ScreenPoint’s AI system, Transpara, known for improving early cancer detection. Research published in Radiology highlights the combined strength of Transpara’s lesion detection and Biomediq’s texture analysis in elevating risk prediction. The acquisition underscores ScreenPoint’s commitment to advance breast cancer detection tools, offering radiologists enhanced reliability and efficiency in diagnosis. The collaboration also signifies a strategic step towards improved resource utilization and patient detection stratification.
Sectors
- Healthcare Technology
- Artificial Intelligence
Geography
- Netherlands – ScreenPoint Medical is headquartered in Nijmegen, Netherlands, marking it as an important geographical location for the company.
- Denmark – Biomediq A/S, the acquired company, indicates its geographical relevance as being based in Denmark.
Industry
- Healthcare Technology – The article is related to the integration of advanced imaging technologies and AI tools in breast cancer risk assessment and detection.
- Artificial Intelligence – ScreenPoint Medical utilizes AI through its product, Transpara, to aid in breast cancer detection.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ScreenPoint Medical | Acquiring Company | Company | A company focused on leveraging AI for breast cancer screening and detection. |
| Biomediq A/S | Target Company | Company | Specializes in the development of quantitative imaging biomarkers for cancer detection. |
| Andreas D. Lauritzen | Researcher/Team Member | Person | First author of a relevant research paper who will join ScreenPoint Medical to enhance Transpara's capabilities. |
| Nico Karssemeijer | Co-founder and Chief Scientist | Person | Co-founder and Chief Scientist of ScreenPoint Medical. |
| Mads Nielsen | Co-founder and Advisor | Person | Co-founder of Biomediq and will remain as an advisor post-acquisition. |